Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 9, 2007, Pages 972-978

  Um, S W ^a   Lee, S W ^a   Kwon, S Y ^a,b   Yoon, H I ^a,b   Park, K U ^b   Song, J ^b   Lee, C T ^a,b   Lee, Jae Ho ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Drug; Monitoring; Tuberculosis

Indexed keywords

ACETYLISONIAZID; CREATININE; DEACETYLRIFAMPICIN; DRUG METABOLITE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAMPICIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; HUMAN; INGESTION; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; VENOUS BLOOD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; LINEAR MODELS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 34548758508     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
2. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
3. Hong Y P, Kim S J, Lew W J, Lee S H, Lee E K. Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. Int J Tuberc Lung Dis 1998; 2: 365-371.
4. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183.
5. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-293.
6. Gurumurthy P, Ramachandran G, Hemanth Kumar A K, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-4475.
7. Tappero J W, Bradford W Z, Agerton T B, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-469.
8. Kimerling M E, Phillips P, Patterson P, Hall M, Robinson C A, Dunlap N E. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-1183.
9. McIlleron H, Wash P, Burger A, Norman J, Folb P I, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-1177.
10. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33: 229-234.
11. van Crevel R, Alisjahbana B, de Lange W C, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002; 6: 497-502.
12. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491.
13. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-1347.
14. Mehta J B, Shantaveerapa H, Byrd R P Jr., Morton S E, Fountain K, Roy T M. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-1524.
15. Morehead R S. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels. South Med J 2000; 93: 507-510.
16. Gilljam M, Berning S K, Peloquin C A, Strandvik B, Larsson L O. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999; 14: 347-351.
17. Holdiness M R. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9: 511-544.
18. Peloquin C A. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77: 1253-1262.
19. Song S H, Jun S H, Park K II, et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1331-1338.
20. Peloquin C A, Bulpitt A E, Jaresko G S, Jelliffe R W, James G T, Nix D K. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18: 1205-1211.
21. Peloquin C A, Bulpitt A E, Jaresko G S, Jelliffe R W, Childs J M, Nix D K. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 43: 568-572.
22. Peloquin C A, Namdar R, Dodge A A, Nix D E. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3: 703-710.
23. Peloquin C A, Namdar R, Singleton M D, Nix D E. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115: 12-18.
24. Peloquin C A, Jaresko G S, Yong C I, Keung A C, Bulpitt A E, Jelliffe R W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41: 2670-2679.
25. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
26. Woo J, Chan C, Chan R, Cheung W, Or K, Chan K. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. J Med 1995; 26: 279-294.
27. Weber W W, Hein D W. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
28. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.